1. What Is AOD-9604
AOD-9604 (Anti-Obesity Drug 9604) is a synthetic 16-amino acid peptide derived from the C-terminal fragment of human growth hormone (hGH), corresponding to residues 176–191. It differs from the native hGH sequence by a single substitution: tyrosine replaces phenylalanine at the N-terminal position. Its sequence — Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe — includes an intramolecular disulfide bond between Cys⁷ and Cys¹⁴, which constrains the peptide into a partially cyclic conformation.
The compound was originally developed by Metabolic Pharmaceuticals (later Calzada Limited) in Australia during the late 1990s and 2000s. The rationale was to isolate the lipolytic (fat-metabolizing) activity of growth hormone from its growth-promoting and diabetogenic effects. Researchers hypothesized that the C-terminal region of hGH was responsible for fat metabolism independent of the receptor-binding domain that drives IGF-1 production and tissue growth.
AOD-9604 was investigated as an oral anti-obesity drug. Following a Phase 2B clinical trial that failed to demonstrate statistically significant weight loss versus placebo, development was terminated in 2007. The compound has never been approved for medical use in any jurisdiction. It is currently circulated in the gray-market research peptide space, primarily as an injectable product — a route of administration for which no human efficacy or safety data from controlled trials exists.
2. Mechanism of Action
AOD-9604 was designed to mimic the lipolytic activity of the C-terminal domain of human growth hormone without engaging the somatotropin receptor responsible for IGF-1 production. The proposed mechanism has been studied primarily in animal models, and the specific molecular pathways are not fully characterized in humans.
β₃-Adrenergic Receptor Upregulation
The primary evidence for AOD-9604's mechanism comes from a 2001 study by Heffernan et al. (Endocrinology, 142(12):5182–5189). In obese mice, chronic AOD-9604 treatment enhanced lipolysis — the breakdown of stored triglycerides into free fatty acids. Critically,β₃-adrenergic receptor knockout mice showed no response to AOD-9604, establishing that β₃-AR upregulation is necessary for the compound's lipolytic effect in this model. The β₃-adrenergic receptor is expressed primarily on adipocytes and is involved in thermogenesis and fat mobilization.
Lipogenesis Inhibition
In addition to stimulating fat breakdown, animal studies suggested AOD-9604 inhibits lipogenesis — the synthesis of new fatty acids. This dual action (increased lipolysis plus decreased lipogenesis) was the basis for the compound's commercial development as an anti-obesity agent. However, these effects were observed in rodent models and did not translate into clinically meaningful weight loss in the human Phase 2B trial.
No IGF-1 Stimulation
A key design feature of AOD-9604 is that it does not stimulate insulin-like growth factor 1 (IGF-1) production. Full-length hGH promotes tissue growth and can impair glucose tolerance through IGF-1. Early human trials confirmed that AOD-9604 did not raise IGF-1 levels — meaning it avoids the growth-promoting and diabetogenic effects of full-length growth hormone. This was the primary safety advantage over hGH itself.
Potential Osteogenic Activity
DrugBank (DB06388) notes that AOD-9604 may retain bone-stimulating properties of hGH, with potential direct action on osteoblasts. This has been listed as an investigational indication for osteoporosis, though no clinical trial data supporting bone outcomes in humans has been published.
It is important to note that the β₃-adrenergic receptor mechanism was demonstrated in mice, not humans. Human β₃-AR expression patterns differ from rodent models — particularly in white adipose tissue — which may partly explain why the animal lipolysis results did not translate to significant weight loss in clinical trials.
3. Clinical Evidence
AOD-9604 progressed through early clinical development as an oral anti-obesity drug before its sponsor terminated the program. The human evidence base is limited, and no controlled trial data exists for the injectable route currently sold on the research peptide market.
Regulatory Status
- Not FDA-approved for any indication. Development was terminated by the sponsor in 2007 after clinical failure.
- PCAC voted unanimously against compounding. On December 4, 2024, the FDA's Pharmacy Compounding Advisory Committee voted 0–12 against recommending AOD-9604 (free base and acetate forms) for the 503A Bulks List. The compound had been previously categorized as "nominated but withdrawn" by its original nominator, though FDA continued its evaluation independently.
- FDA cited specific safety concerns: immunogenicity risk for certain routes of administration, complexities with peptide-related impurities and API characterization, limited or no safety-related information, and serious adverse events of unclear causality.
- Banned in sport. AOD-9604 is prohibited by the World Anti-Doping Agency (WADA) and is tested for in competition. Detection methods using LC-MS/MS have been published (Thevis et al., Expert Rev Proteomics, 2014; Cox et al., Drug Test Anal, 2015).
4. What to Look for in a COA
When evaluating a Certificate of Analysis for an AOD-9604 product, confirm the following:
Identity confirmation via mass spectrometry — the intact (oxidized, disulfide-bonded) mass should appear at approximately 1815.1 Da. Common ESI-MS charge states include [M+2H]²⁺, [M+3H]³⁺, and [M+4H]⁴⁺, deconvoluting to the parent mass
HPLC purity of 98% or higher from a named, independent third-party lab — measured by reversed-phase HPLC with UV detection at 214 nm or 280 nm (the N-terminal tyrosine provides a useful 280 nm absorbance)
Disulfide bond integrity verification — the reduced (open-bridge) form has a mass approximately 2 Da higher (~1817 Da) than the oxidized form. A properly folded sample should show minimal reduced-form signal
Absence of intermolecular dimers — disulfide-linked dimers appear at approximately 3628 Da and indicate disulfide scrambling, often caused by alkaline pH exposure during synthesis or storage
Peptide content (net peptide content after accounting for water, counterions, and residual salts) — typical acetate-salt preparations may contain 10–15% TFA or acetate plus 5% or more water, meaning a labeled 5 mg vial may contain approximately 4.0–4.25 mg of active peptide
Water content by Karl Fischer titration and counterion content (TFA or acetate)
Endotoxin and sterility testing for any injectable preparation
A batch or lot number matching the product received, with a verifiable lab reference number from an independent, named testing laboratory
Red flags on an AOD-9604 COA: missing mass spectrometry data (HPLC alone cannot confirm sequence identity, the presence of both cysteines, or the correct disulfide bond), purity below 95%, absence of endotoxin results on injectable products, missing net peptide content data, or a COA that reports only gross weight without accounting for counterions and water content.
For a full walkthrough of evaluating a COA, see our guide to reading a peptide COA.
5. Testing Considerations
AOD-9604 presents specific analytical and quality challenges due to its disulfide bond, its 16-residue length placing it at the boundary of small and mid-size peptides, and the absence of pharmaceutical-grade manufacturing standards for gray-market products.
Analytical Methods
The standard analytical approach uses reversed-phase HPLC with UV detection for purity assessment, combined with mass spectrometry for identity confirmation. UV detection is typically performed at 214–220 nm (amide bond absorbance, universal for peptides) and at 280 nm (tyrosine absorbance, specific to this peptide). For mass spectrometry, electrospray ionization (ESI-MS) produces multiply charged ions that deconvolute to the parent mass of 1815.1 Da. MALDI-TOF is also suitable for peptides in this mass range and predominantly produces singly charged [M+H]⁺ ions. Published anti-doping methods use LC-MS/MS for detection in biological matrices.
Disulfide Bond Verification
The Cys⁷-Cys¹⁴ disulfide bond is critical to AOD-9604's structure. Mass spectrometry can distinguish the oxidized (intact bridge, ~1815 Da) from the reduced (open bridge, ~1817 Da) form — a 2 Da mass shift. Running a sample under reducing conditions (with DTT or TCEP) and comparing the mass to the native sample confirms whether the disulfide is intact. An elevated proportion of reduced-form peptide indicates degradation or improper handling during synthesis.
Common Impurities
Synthesis-related impurities in AOD-9604 include truncated sequences (peptides missing one or more residues from the N- or C-terminus), deletion sequences (internal residue omissions), racemized residues (particularly D-amino acid contamination producing diastereomers), and misfolded disulfide isoforms. On HPLC, truncated sequences typically elute earlier than the target (more hydrophilic), while deletion sequences and hydrophobic modifications elute later. A shoulder on the main peak may indicate a diastereomer from racemization during synthesis. Residual trifluoroacetic acid (TFA) from HPLC purification is another common contaminant.
Stability and Storage
As a lyophilized powder, AOD-9604 should be stored at -20°C in sealed, desiccated containers protected from light. The vial should be allowed to reach room temperature before opening to prevent moisture condensation onto the powder. Once reconstituted, solutions should be stored at 2–8°C for short-term use or aliquoted and frozen to avoid repeated freeze-thaw cycles.
The disulfide bond is the primary stability concern. While stable under mildly acidic to neutral conditions, alkaline pH promotes disulfide exchange — leading to intermolecular dimers (~3628 Da) and higher-order aggregates. The N-terminal tyrosine is less susceptible to oxidation than methionine or tryptophan residues, but standard precautions against oxidative degradation still apply. At low concentrations, non-specific adsorption to plastic surfaces can cause significant sample loss; low-protein-binding tubes are recommended for analytical work.
Substitution and Misidentification Risks
AOD-9604 is closely related to the unmodified hGH Fragment 176-191, which has phenylalanine instead of tyrosine at the N-terminus. The two peptides differ by a single hydroxyl group (16 Da mass difference), which is detectable by high-resolution mass spectrometry but could be missed by low-resolution instruments. HPLC alone cannot reliably distinguish the two. The 280 nm UV absorbance from the tyrosine residue provides a secondary check — the unmodified phenylalanine-containing fragment absorbs weakly at 280 nm, while AOD-9604's tyrosine gives a stronger signal at this wavelength.
Net Peptide Content
AOD-9604 is commonly supplied as an acetate or TFA salt. The acetate salt has a higher apparent molecular weight than the free peptide due to counterion mass. When accounting for water content (typically 3–7% by Karl Fischer) and counterions (TFA or acetate, potentially 10–15% by weight), net peptide content of lyophilized powders typically ranges from 70–88%. A 5 mg vial may therefore contain only 3.5–4.4 mg of active peptide. A properly detailed COA should report both gross weight and net peptide content, with the analytical method (nitrogen analysis or amino acid analysis) used to determine peptide content clearly stated.
Summary
AOD-9604 is a synthetic 16-amino acid peptide fragment derived from the C-terminal domain of human growth hormone. It was developed as an oral anti-obesity drug but failed to demonstrate clinically meaningful weight loss in a Phase 2B trial, and development was terminated in 2007. It is not approved for medical use in any country, the FDA's PCAC voted unanimously against recommending it for compounding, and it is banned in sport by WADA. No controlled human trial data exists for the injectable route currently sold on the gray market.
When evaluating an AOD-9604 product, prioritize third-party lab testing showing HPLC purity at or above 98%, mass spectrometric identity confirmation at approximately 1815.1 Da with verification of disulfide bond integrity, net peptide content determination, and — for any injectable preparation — verified endotoxin and sterility testing from an independent laboratory.